Overview

Phase 1 Study of PYX-106 in Solid Tumors

Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Pyxis Oncology, Inc